Daniel Arias Analyst PerformanceManaging Director at Stifel NicolausDaniel Arias is a stock analyst at Stifel Nicolaus in the healthcare sector, covering 18 publicly traded companies. Over the past year, Daniel Arias has issued 32 stock ratings, including buy and hold recommendations. While full access to Daniel Arias' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniel Arias' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings51 Last 9 YearsBuy Recommendations65.12% 28 Buy RatingsCompanies Covered18 Unique Companies Ratings Distribution43RatingsDistribution of strong buy, buy, hold, and sell ratings by Daniel Arias.RatingPercentageCount Strong Buy0.0%0 ratings Buy65.1%28 ratings Hold34.9%15 ratings Sell0.0%0 ratingsOut of 43 total stock ratings issued by Daniel Arias at Stifel Nicolaus, the majority (65.1%) have been Buy recommendations, followed by 34.9% Hold.Best & Worst CallsBest Call0000.0%GHFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%MXCTMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ61.1% of companies on NASDAQ11 companiesNYSE38.9% of companies on NYSE7 companiesDaniel Arias, an analyst at Stifel Nicolaus, currently covers 18 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare18 companies100.0%Daniel Arias of Stifel Nicolaus specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageLIFE SCIENCES TOOLS & SERVICES14 companies77.8%HEALTHCARE PROVIDERS & SERVICES3 companies16.7%BIOTECHNOLOGY1 company5.6% About Daniel AriasDan Arias joined Stifel in June 2019. He is a Managing Director in the Healthcare sector, covering Life Sciences and Diagnostics. Before joining Stifel, Dan previously covered Life Sciences and Diagnostics at Citigroup and UBS. He previously worked in the research microbiology lab at Wyeth Pharmaceuticals. Dan is a graduate of Mary Washington College and Rutgers Business School.Follow on LinkedIn Daniel Arias' Ratings History at Stifel Nicolaus Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsQGENQiagen8/7/2026Set Price Target$42.10$40.00$0.0000.00% ROIWATWaters8/5/2026Set Price Target$395.56$420.00$0.0000.00% ROITMOThermo Fisher Scientific8/5/2026Set Price Target$567.68$650.00$0.0000.00% ROIBRKRBruker8/5/2026Set Price Target$49.76$50.00$0.0000.00% ROITEMTempus AI8/3/2026Lower Price Target$43.87$50.00Hold$0.0000.00% ROIMTDMettler-Toledo International8/3/2026Boost Price Target$1,418.55$1,600.00Buy$0.0000.00% ROIGHGuardant Health7/31/2026Boost Price Target$168.96$180.00Buy$0.0000.00% ROIILMNIllumina7/31/2026Boost Price Target$197.86$225.00Buy$0.0000.00% ROIAVTRAvantor7/30/2026Boost Price Target$13.84$15.00Hold$0.0000.00% ROIDHRDanaher7/22/2026Lower Price Target$175.01$220.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. QGENQiagen5/18/2026Set Price Target$33.00$36.00Hold$0.0000.00% ROIMTDMettler-Toledo International5/18/2026Lower Price Target$1,062.40$1,400.00Buy$0.0000.00% ROIALMRAlamar Biosciences5/12/2026Initiated Coverage$23.88$28.00Buy$0.0000.00% ROIBRKRBruker5/8/2026Set Price Target$42.82$45.00$0.0000.00% ROIRVTYRevvity5/6/2026Lower Price Target$93.65$100.00Hold$0.0000.00% ROITMOThermo Fisher Scientific4/24/2026Lower Price Target$466.93$600.00Buy$0.0000.00% ROICDXSCodexis3/12/2026Set Price Target$1.72$5.00$0.0000.00% ROITXG10x Genomics3/2/2026Boost Price Target$23.05$25.00Buy$0.0000.00% ROITEMTempus AI2/25/2026Set Price Target$54.17$60.00$0.0000.00% ROIGHGuardant Health2/20/2026Boost Price Target$106.38$130.00Buy$0.0000.00% ROITXG10x Genomics2/13/2026Boost Price Target$17.51$20.00Buy$0.0000.00% ROIQGENQiagen2/6/2026Set Price Target$51.22$50.00Hold$0.0000.00% ROITECHBio-Techne2/5/2026Set Price Target$67.23$65.00Hold$0.0000.00% ROIILMNIllumina1/20/2026Boost Price Target$141.65$155.00Buy$0.0000.00% ROITMOThermo Fisher Scientific1/9/2026Boost Price Target$606.16$700.00Buy$0.0000.00% ROIGHGuardant Health1/9/2026Boost Price Target$108.74$120.00Buy$0.0000.00% ROIBLLNBilliontoone12/1/2025Initiated Coverage$130.18$145.00Buy$0.0000.00% ROIEXASExact Sciences11/28/2025Reiterated Rating$101.35$105.00Hold$0.0000.00% ROIMTDMettler-Toledo International11/10/2025Boost Price Target$1,438.69$1,600.00Buy$0.0000.00% ROIEXASExact Sciences11/4/2025Boost Price Target$66.98$80.00Buy$0.0000.00% ROIGHGuardant Health9/25/2025Set Price Target$62.81$73.00$0.0000.00% ROIGHGuardant Health9/25/2025Boost Price Target$60.28$70.00Buy$0.0000.00% ROIBRKRBruker8/5/2025Set Price Target$34.72$40.00Hold$00.0000.00% ROIAVTRAvantor8/4/2025Set Price Target$11.41$12.00Hold$00.0000.00% ROIRVTYRevvity7/29/2025Lower Price Target$95.66$110.00Hold$000.0000.00% ROIBRKRBruker5/8/2025Lower Price Target$40.95$48.00Hold$00.0000.00% ROITECHBio-Techne5/8/2025Lower Price Target$48.76$60.00Hold$00.0000.00% ROIGHGuardant Health5/1/2025Boost Price Target$48.06$60.00Buy$00.0000.00% ROIAVTRAvantor4/28/2025Downgrade$12.93$14.00Hold$0.0000.00% ROITMOThermo Fisher Scientific4/24/2025Lower Price Target$422.94$620.00Buy$000.0000.00% ROIA new income category is drawing serious money - here's why (Ad)Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.Watch the short briefing to see how this income approach worksDHRDanaher3/14/2025Upgrade$203.96$260.00Buy$000.0000.00% ROIMXCTMaxCyte3/12/2025Lower Price Target$3.47$9.00Buy$0.0000.00% ROIGHGuardant Health2/21/2025Boost Price Target$45.85$53.00Buy$000.0000.00% ROIBRKRBruker2/14/2025Lower Price Target$50.29$57.00Hold$00.0000.00% ROITXG10x Genomics2/13/2025Lower Price Target$11.52$18.00Buy$00.0000.00% ROIAVTRAvantor2/10/2025Lower Price Target$19.15$26.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupWeiss RatingsUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
